[go: up one dir, main page]

WO2005065640A8 - Compositions of buccal dosage forms for extended drug release and the process of preparing such compositions - Google Patents

Compositions of buccal dosage forms for extended drug release and the process of preparing such compositions

Info

Publication number
WO2005065640A8
WO2005065640A8 PCT/IN2005/000003 IN2005000003W WO2005065640A8 WO 2005065640 A8 WO2005065640 A8 WO 2005065640A8 IN 2005000003 W IN2005000003 W IN 2005000003W WO 2005065640 A8 WO2005065640 A8 WO 2005065640A8
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
preparing
dosage forms
drug release
buccal dosage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2005/000003
Other languages
French (fr)
Other versions
WO2005065640A1 (en
Inventor
Rajesh Jain
Kour Chand Jindal
Sukhjeet Singh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Panacea Biotec Ltd
Original Assignee
Panacea Biotec Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panacea Biotec Ltd filed Critical Panacea Biotec Ltd
Priority to YUP-2005/0835A priority Critical patent/RS20050835A/en
Publication of WO2005065640A1 publication Critical patent/WO2005065640A1/en
Publication of WO2005065640A8 publication Critical patent/WO2005065640A8/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Buccal dosage form compositions, preferably of poorly bioavailable drug(s), or drug(s) which undergo extensive presystematic metabolism, are provided. The compositions provide extended release of the drug in the oral cavity, and are preferably in the taste masked form. A process of preparing of such compositions is also provided.
PCT/IN2005/000003 2004-01-06 2005-01-05 Compositions of buccal dosage forms for extended drug release and the process of preparing such compositions Ceased WO2005065640A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
YUP-2005/0835A RS20050835A (en) 2004-01-06 2005-01-05 Compositions of buccal dosage forms for extended drug release and the process of preparing such compositions

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN24/DEL/2004 2004-01-06
IN26/DEL/2004 2004-01-06
IN26DE2004 2004-01-06
IN24DE2004 2004-01-06

Publications (2)

Publication Number Publication Date
WO2005065640A1 WO2005065640A1 (en) 2005-07-21
WO2005065640A8 true WO2005065640A8 (en) 2005-12-08

Family

ID=34751866

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2005/000003 Ceased WO2005065640A1 (en) 2004-01-06 2005-01-05 Compositions of buccal dosage forms for extended drug release and the process of preparing such compositions

Country Status (2)

Country Link
RS (1) RS20050835A (en)
WO (1) WO2005065640A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007096906A2 (en) * 2006-02-27 2007-08-30 Panacea Biotec Ltd. Novel buccoadhesive compositions and process of preparation thereof
CN100450548C (en) * 2006-12-22 2009-01-14 江苏奥赛康药业有限公司 Oral patches containing pdacrilin resin composition and its preparing method
WO2008155620A1 (en) * 2007-06-20 2008-12-24 Develco Pharma Schweiz Ag Dosage form containing dispersible matrix of sustained release granules
US8133506B2 (en) 2008-03-12 2012-03-13 Aptalis Pharmatech, Inc. Drug delivery systems comprising weakly basic drugs and organic acids
EP3108876A1 (en) * 2011-10-13 2016-12-28 Jaleva Pharmaceuticals LLC Methods and compositions for rapid transbuccal delivery of active agents
EP2906210A4 (en) * 2012-10-12 2016-06-08 Jaleva Pharmaceuticals Llc Method of preparing resin tinctures
EP2925273A4 (en) 2012-11-28 2016-08-31 Jaleva Pharmaceuticals Llc Dual chamber applicator
CN105232502A (en) * 2015-02-10 2016-01-13 万全万特制药江苏有限公司 Orally disintegrating tablet containing polacrilin potassium-fluoxertine hydrochloride compound and preparation method of orally disintegrating tablet
ES2983269T3 (en) * 2015-07-23 2024-10-22 Athena Pharmaceutiques Sas Composition of zolpidem and its preparation process
CN114344241B (en) * 2021-12-15 2024-01-30 悦康药业集团安徽天然制药有限公司 Polyacrylic resin modified adsorption drug carrier and preparation method thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1238072B (en) * 1990-01-19 1993-07-03 Sclavo Spa PHARMACEUTICAL COMPOSITIONS AND DOSAGE FORMS FOR ORAL ADMINISTRATION OF CALCITONIN
AU3455297A (en) * 1996-07-11 1998-02-09 Farmarc Nederland Bv Pharmaceutical composition containing acid addition salt of basic drug
DE19932603A1 (en) * 1999-07-13 2001-01-25 Gruenenthal Gmbh Multi-layer film containing active substance made of in-situ cross-linked hydrophilic polymers
JP2004532838A (en) * 2001-03-02 2004-10-28 ブリストル−マイヤーズ スクイブ カンパニー Compounds useful as melanocortin receptor modulators and pharmaceutical compositions containing them
US7276246B2 (en) * 2003-05-09 2007-10-02 Cephalon, Inc. Dissolvable backing layer for use with a transmucosal delivery device

Also Published As

Publication number Publication date
RS20050835A (en) 2007-08-03
WO2005065640A1 (en) 2005-07-21

Similar Documents

Publication Publication Date Title
AP1908A (en) A pharmaceutical composition for the treatment of cardiovascular and cerebrovascular diseases
EP1806149A4 (en) Solid medicinal preparation improved in solubility and stability and process for producing the same
IL220480A0 (en) 1-benzyl-pyrimidine-2,4-dione derivatives as dipeptidyl peptidase inhibitors , preparation method thereof, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments
WO2008002245A3 (en) Imidazol-pyrimidine derivatives for treatment of diseases related to glycogen synthase kinase (gsk3)
IL163831A (en) Derivatives of aminoindazoles, pharmaceutical compositions comprising them, process for their preparation and use thereof
AU2003229555A1 (en) Oral administration form for difficulty soluble basic active ingredients which are applied orally
IL183982A0 (en) Controlled release formulation for oral administration for treating diabetes containing metformin and methods for the preparation thereof
ZA200608029B (en) Nitrogenous fused-ring derivatives, medicinal compositions containing the derivatives, and use thereof as drugs
IL204947A0 (en) Phenylacetamido-thiazole derivatives, process for their preparation and their use in the manufacture of medicaments, pharmaceutical compositions and kits comprising them
IL162765A (en) Diazabicycle derivatives, processes for their preparation, pharmaceutical compositions comprising them and their medical use
IL173195A0 (en) Cyclovinylazoline derivatives, their preparation and pharmaceutical compositions containing them
IL181022A0 (en) Novel benzamidine derivatives, process for the preparation thereof and pharmaceutical compositions comprising the same
WO2007144169A3 (en) Entacapone-derivatives
EP1757273A4 (en) Preparation for oral administration
HUP0401522A2 (en) New 4-benzylidene-piperidine derivatives, pharmaceutical compositions containing the same and process for their preparation
AU2003221699A1 (en) Pharmaceutical preparation for taste masking
ZA200704246B (en) Solid medicinal preparation improved in solubility and stability and process for producing the same
WO2005065640A8 (en) Compositions of buccal dosage forms for extended drug release and the process of preparing such compositions
HUP0401523A3 (en) Indole-2-carboxamide derivatives, pharmaceutical compositions containing them and process for producing them
AU2003232941A1 (en) N-mercaptoacyl phenyalanine derivatives, process for their preparation, and pharmaceutical compositions containing them
AU2003208673A1 (en) Pacifier for administering flavour substances
EP1731139A4 (en) S/o type pharmaceutical preparation and process for producing the same
WO2004009085A3 (en) Taste masked sumatriptan tablets and processes for their preparation
EP1811967A4 (en) Methods and formulations for making pharmaceutical compositions containing bupropion
EP1594531A4 (en) Storage-stable and bio-stable formulations of ace inhibitors, and methods for preparation thereof

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: P-2005/0835

Country of ref document: YU

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WR Later publication of a revised version of an international search report
CFP Corrected version of a pamphlet front page

Free format text: UNDER (54) PUBLISHED TITLE REPLACED BY CORRECT TITLE

NENP Non-entry into the national phase in:

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

122 Ep: pct application non-entry in european phase